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A B S T R A C T
Background
This is an updated version of the Cochrane Review previously published in 2016.
Epilepsy is a common neurological disorder, a@ecting 0.5% to 1% of the population. For nearly 30% of these people, their epilepsy is
resistant to currently available drugs. Pharmacological treatment remains the first choice to control epilepsy. Lamotrigine is one of the
newer antiepileptic drugs. Lamotrigine, in combination with other antiepileptic drugs (add-on), can reduce seizures, but with some adverse
e@ects.
Objectives
To determine the e@ects of lamotrigine on (1) seizures, (2) adverse-e@ect profile, and (3) cognition and quality of life, compared to placebo,
when used as an add-on treatment for people with drug-resistant focal epilepsy.
Search methods
For the latest update of the review, we searched the following databases on 9 March 2020: Cochrane Register of Studies (CRS Web),
MEDLINE (Ovid, 1946 to March 06, 2020). CRS Web includes randomized or quasi-randomized, controlled trials from PubMed, EMBASE,
ClinicalTrials.gov, the World Health Organization International Clinical Trials Registry Platform (ICTRP), the Cochrane Central Register of
Controlled Trials (CENTRAL), and the Specialized Registers of Cochrane Review Groups including Epilepsy. No language restrictions were
imposed.
Selection criteria
Randomised placebo-controlled trials of people with drug-resistant focal epilepsy of any age, in which an adequate method of concealment
of randomisation was used. The studies were double-, single- or unblinded, placebo-controlled. For cross-over studies, the first treatment
period was treated as a parallel trial. Eligible participants were adults or children with drug-resistant focal epilepsy.
Data collection and analysis
For this update, two review authors independently assessed the trials for inclusion, and extracted data. Outcomes included 50% or greater
reduction in seizure frequency, treatment withdrawal (any reason), adverse e@ects, e@ects on cognition and quality of life. Primary analyses
were by intention-to-treat. Sensitivity best- and worse-case analyses were undertaken to account for missing outcome data. Pooled
risk ratios (RRs) with 95% confidence intervals (95% Cls) were estimated for the primary outcomes of seizure frequency and treatment
withdrawal. For adverse e@ects, we calculated pooled RRs and 99% Cls.
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Main results
We did not identify any new studies for this update, therefore, the results and conclusions are unchanged.
In previous updates of this review, the authors found five parallel add-on studies, eight cross-over studies in adults or children with drug-
resistant focal epilepsy, and one parallel add-on study with a responder-enriched design in infants. In total, these 14 studies included 1806
eligible participants (38 infants, 199 children, 1569 adults). Baseline phases ranged from four to 12 weeks; treatment phases from eight to
36 weeks. Overall, 11 studies (1243 participants) were rated as having low risk of bias, and three (697 participants) had unclear risk of bias
due to lack of reported information around study design. E@ective blinding of studies was reported in four studies (563 participants).
The overall risk ratio (RR) for 50% or greater reduction in seizure frequency was 1.80 (95% CI 1.45 to 2.23; 12 trials, 1322 participants (adults
and children); moderate-certainty evidence) indicating that lamotrigine was significantly more e@ective than placebo in reducing seizure
frequency. The overall RR for treatment withdrawal (for any reason) was 1.11 (95% CI 0.91 to 1.37; 14 trials; 1806 participants; moderate-
certainty evidence). The adverse events significantly associated with lamotrigine were: ataxia, dizziness, diplopia (double vision), and
nausea. The RR of these adverse e@ects were as follows: ataxia 3.34 (99% Cl 2.01 to 5.55; 12 trials; 1525 participants; high-certainty
evidence); dizziness 2.00 (99% Cl 1.52 to 2.64;13 trials; 1768 participants; moderate-certainty evidence); diplopia 3.79 (99% Cl 2.15 to
6.68; 3 trials, 944 participants; high-certainty evidence); nausea 1.81 (99% Cl 1.22 to 2.68; 12 studies,1486 participants; moderate-certainty
evidence). The limited data available precluded any conclusions about e@ects on cognition and quality of life. No important heterogeneity
between studies was found for any of the outcomes. Overall, we assessed the evidence as high to moderate certainty, due to incomplete
data for some outcomes.
Authors' conclusions
Lamotrigine as an add-on treatment for drug-resistant focal seizures appears to be e@ective in reducing seizure frequency, and seems to
be fairly well-tolerated. However, the trials were of relatively short duration and provided no evidence for the long term. Further trials are
needed to assess the long-term e@ects of lamotrigine, and to compare lamotrigine with other add-on drugs.
P L A I N   L A N G U A G E   S U M M A R Y
Lamotrigine add-on therapy for drug-resistant focal epilepsy
Background
Epilepsy is a disorder in which unexpected electrical discharges from the brain cause seizures. Approximately one-third of patients with
epilepsy continue to have seizures, despite treatment with presently used (older) antiepileptic drugs (AEDs). In addition, the older AEDs
have a lot of adverse e@ects. Therefore, the development of e@ective new therapies for the treatment of drug-resistant seizures is of
considerable importance. As a result, a range of new AEDs has been developed as 'add-on' treatments. Lamotrigine is one of these drugs.
Aims of the review
This review aimed to determine the e@ects of lamotrigine on seizures, adverse e@ects, cognition (ability to learn and understand) and
quality of life compared to placebo controls, when used as an add-on treatment for people with focal epilepsy that would not respond
to existing AEDs. For this update, we did not identify any new studies to add, and thus, the conclusions remain unchanged. The review
included 14 randomised controlled trials with a total number of 1806 participants.
Results
Lamotrigine, used in combination with other AEDs in patients who have drug-resistant focal epilepsy can decrease the frequency of
seizures further. However, adding lamotrigine to the usual treatment is more oMen associated with an increase in adverse e@ects such as
unsteadiness (ataxia), dizziness, double vision (diplopia), and nausea.
Certainty of the evidence
We assessed the trials with regards to risk of bias and overall we judged them as low to unclear. We rated the certainty of the evidence
as high to moderate.
Conclusions
Further high-quality research is needed to fully evaluate the e@icacy and tolerability of lamotrigine and compare it with other newer AEDs.
The evidence is current to 9 March 2020.
Lamotrigine add-on therapy for drug-resistant focal epilepsy (Review)














































































S U M M A R Y   O F   F I N D I N G S
 
Summary of findings for the main comparison.
Lamotrigine versus placebo for drug-resistant focal epilepsy




Illustrative comparative risks* (95% CI)
Assumed risk Corresponding risk
Outcomes
Placebo Lamotrigine













157 per 1000 283 per 1000
(223 to 350)
RR 1.80









159 per 1000 176 per 1000
(144 to 217)
RR 1.11





RR > 1 indicates outcome is more likely in
lamotrigine group
Ataxia 45 per 1000 150 per 1000
(90 to 250)
RR 3.34





RR > 1 indicates outcome is more likely in
lamotrigine group
Diplopia 61 per 1000 233 per 1000
(132 to 410)
RR 3.79 (2.15 TO 6.68) 944
(3 studies)
⊕⊕⊕⊕high1,3 RR > 1 indicates outcome is more likely in
lamotrigine group
Dizziness 128 per 1000 255 per 1000
(194 to 337)
RR 2.00





RR > 1 indicates outcome is more likely in
lamotrigine group
Fatigue 113 per 1000 93 per 1000
(62 to 138)
RR 0.82 1552 ⊕⊕⊕⊝
moderate1









































































































































(99% CI 0.55 to 1.22) (12 studies)
Nausea 83 per 1000 150 per 1000
(101 to 222)
RR 1.81





RR > 1 indicates outcome is more likely in
lamotrigine group
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes4. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
1 Downgraded once for imprecision: Number of events (< 400) did not su@ice the optimal information size.
2 Downgraded once for inconsistency: Significant statistical heterogeneity was detected (P < 0.10).
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B A C K G R O U N D
This review is an update of the Cochrane Review previously
published in 2016, Issue 6 of the Cochrane Database of Systematic
Reviews (Ramaratnam 2016).
Description of the condition
Epilepsy is characterised by recurrent and unprovoked seizures,
constituting a transient sign and symptom of abnormal, excessive
electrical activity in the cerebral cortex (Fisher 2005). Epilepsy
is one of the most common serious neurological conditions
worldwide, with significant psychosocial and physical morbidity.
Its management requires expertise and good pharmacological
knowledge of the available options (Lyer 2014). The condition
a@ects approximately 50 million people worldwide. The total
annual cost in Europe is approximately 15.5 billion Euros (Mula
2013). Between 2% and 3% of the population will be given a
diagnosis of epilepsy at some time in their lives (Hauser 1993),
the majority of whom will become seizure free. However, up to
30% will continue to have seizures, refractory to treatment with
adequate doses of antiepileptic drugs (AEDs), which are oMen
given in combination (Cockerell 1995). There is no internationally
accepted definition of "drug-resistant". For the purposes of this
review, people will be considered to be drug-resistant if they have
failed to respond to a minimum of two AEDs, given as monotherapy.
The majority of drug-resistant people have focal onset (also called
focal or localisation-related) seizures. In other words, seizures start
in one part of the brain and during the course of the seizure, the
abnormal electrical activity remains localised or spreads to other
parts of the brain. Focal seizures can be divided into three types:
simple focal; complex focal, and secondarily generalised tonic-
clonic seizures (Commission 1989).
Description of the intervention
Although more than a dozen new AEDs have entered the market
since 1993, up to 30% of patients remain refractory to current
treatments. Thus, a concerted e@ort continues to identify and
develop new therapies that will help these patients (Barker-Haliski
2014). Pharmacological treatment remains the first choice for
controlling epilepsy (Loscher 2002), although recent decades have
seen advances in vagal stimulation (Panebianco 2015), and surgery
(West 2019). Given that our standard drugs (e.g. carbamazepine,
phenytoin, valproate, gabapentin) do not leave all people seizure
free and are not without adverse e@ects (Panebianco 2018),
over the past 20 to 25 years, there has been renewed interest
in the development of newer AEDs. Lamotrigine is a relatively
more recent AED, widely used in the treatment of epilepsy as
adjunctive treatment for focal, secondarily generalised, and tonic-
clonic seizures in patients with drug-resistant epilepsy, and bipolar
disorder (Yamamoto 2012).
How the intervention might work
Lamotrigine was approved by the Food and Drug Administration
in the USA in 1994 for use in focal-onset seizures. It was
ultimately approved for monotherapy in 1998. Lamotrigine is
e@ective against a broad spectrum of seizure types and has a
favourable metabolic profile. It has gained widespread use in the
USA as both an immediate and an extended-release agent (Moore
2012). Lamictal (GlaxoSmithKline) is considered the reference
drug (Girolineto 2012). In vitro pharmacological studies suggest
that the main mechanism of action of lamotrigine is to inhibit
voltage-sensitive sodium channels, thereby stabilising neuronal
membranes and consequently modulating presynaptic transmitter
release of excitatory amino acids, e.g. glutamate and aspartate
(Leach 1995). Lamotrigine has been demonstrated to be e@ective as
both an antiepileptic drug and a mood stabiliser (Vajda 2013).
Why it is important to do this review
In this review, we summarise evidence from randomised controlled
trials where the e@icacy and tolerability of lamotrigine for people
with drug-resistant focal epilepsy have been investigated, in order
to aid clinical decision-making when considering lamotrigine as
add-on treatment within this population. Antiepileptic drugs may
impair people's cognitive abilities, and in this review, we include
outcomes that assess cognitive e@ects. In addition, we have chosen
to include quality of life (QOL) outcomes, to assess the global
impact of this drug on people's well-being.
O B J E C T I V E S
To determine the e@ects of lamotrigine on (1) seizures, (2) adverse-
e@ect profile, and (3) cognition and quality of life, compared to
placebo, when used as an add-on treatment for people with drug-
resistant focal epilepsy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included trials that met all the following criteria.
1. Randomised controlled trials, in which an adequate method
of concealment of randomisation was used (e.g. allocation of
sequentially sealed packages of medication, sealed opaque
envelopes, telephone randomisation).
2. Double-blind, single-blind trials and unblinded trials.
3. Placebo-controlled trials.
4. Parallel group and cross-over studies. For cross-over studies,
the first treatment period was treated as a parallel trial, for the
purposes of analysis of e@icacy and safety data (i.e. only data
from the first treatment period was used).
Types of participants
Individuals of any age with focal epilepsy (i.e. experiencing
simple focal, complex focal, or secondarily generalised tonic-clonic
seizures) who had failed to respond to at least two antiepileptic
drugs ((AEDs) (drug-resistant epilepsy).
Types of interventions
1. The treatment group received lamotrigine in addition to
conventional AEDs treatment.
2. The control group received conventional AED treatment plus a
matched placebo, or 'no treatment' control.
Types of outcome measures
Primary outcome
FiIy per cent or greater reduction in seizure frequency
The primary outcome was the proportion of participants with a
50% or greater reduction in seizure frequency during the treatment
Lamotrigine add-on therapy for drug-resistant focal epilepsy (Review)
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period, compared to the pre-randomisation baseline frequency. We
chose this outcome as it is commonly reported in this type of study
and can be calculated for studies that do not report this outcome,
provided that baseline seizure data were recorded.
Secondary outcomes
Treatment withdrawal
The proportion of participants who had treatment withdrawn
during the course of the treatment period was chosen as a
measure of global e@ectiveness. Treatment may be withdrawn due
to adverse e@ects, lack of e@icacy, or a combination, and this is
an outcome to which the individual makes a direct contribution.
However, in studies of relatively short duration, such as studies that
would be included in this review, adverse e@ects were likely to be
the main reason for treatment withdrawal.
Adverse e:ects
1. The proportion of participants experiencing any of the following
adverse e@ects, which we considered to be the most common





2. The proportion of participants who experienced the five most
common adverse e@ects in a study, if di@erent from those stated
above.
Cognitive e:ects
The di@erence between intervention and control group(s) means
for cognitive assessments used in the individual studies.
Quality of life (QOL)
The di@erence between intervention and control group(s) means
for QOL assessments used in the individual studies.
Search methods for identification of studies
Electronic searches
Searches were run for the original review in 1999 and subsequent
searches were run in 2001, 2002, 2003, 2005, 2007, 2010, 2011,
2012, 2015, 2017 and 2018. For the latest update, we searched the
following databases on 9 March 2020.
1. Cochrane Register of Studies (CRS Web), using the strategy
outlined in Appendix 1.
2. MEDLINE (Ovid, 1946 to March 06, 2020), using the strategy
outlined in Appendix 2.
CRS Web includes randomized or quasi-randomized, controlled
trials from PubMed, EMBASE, ClinicalTrials.gov, the World Health
Organization International Clinical Trials Registry Platform (ICTRP),
the Cochrane Central Register of Controlled Trials (CENTRAL), and
the Specialized Registers of Cochrane Review Groups including
Epilepsy. We imposed no language restrictions.
Searching other resources
For the original review and this update, we checked reference
lists of reviews and retrieved articles for additional studies, and
performed citation searches on key articles. We contacted experts
in the field for unpublished and ongoing trials, and authors
and manufacturers of lamotrigine (GlaxoSmithKline) for additional
information.
Data collection and analysis
Selection of studies
For this update, two review authors (SR and MP) independently
assessed trials for inclusion. Any disagreements were resolved by
discussion with a third review author (AM). Two review authors (SR
and MP) independently extracted data and assessed the risk of bias
for included trials; again, disagreements were resolved by mutual
discussion.
Data extraction and management
We extracted the following data for each trial, using a data
extraction form.
1. Methods and trial design:
a. method of randomisation;
b. method of allocation concealment;
c. method of blinding;
d. whether any participants had been excluded from reported
analyses;
e. duration of baseline period;
f. duration of treatment period;
g. dose(s) of lamotrigine tested;
h. information on sponsorship and funding.
2. Participant and demographic information:
a. total number of participants allocated to each treatment
group;
b. age and sex;
c. number with focal and generalised epilepsy;
d. seizure types;
e. seizure frequency during the baseline period;
f. number of background drugs.
3. Outcomes:
a. we recorded the number of participants who experienced
each outcome (seeTypes of outcome measures) per
randomised group, and contacted authors of trials for any
missing information.
Assessment of risk of bias in included studies
Two review authors (SR and MP) independently assessed the risk of
bias for each trial, using the Cochrane 'Risk of bias' tool as described
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2019). We discussed and resolved disagreements. We
completed a 'Risk of bias' table for each included study in RevMan
(RevMan 2014). We rated all included studies as having a low, high
or unclear risk of bias on six domains applicable to randomised
controlled trials: randomisation method, allocation concealment,
blinding methods, incomplete outcome data, selective outcome
reporting, and other sources of bias.
Measures of treatment e:ect
We analysed the primary outcome of seizure reduction as a
binary outcome and presented it as a risk ratio. We also
analysed secondary outcomes, including treatment withdrawal
Lamotrigine add-on therapy for drug-resistant focal epilepsy (Review)
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and adverse e@ects as binary outcomes and presented risk ratio.
We had also planned to present cognitive e@ects and quality
of life as continuous outcomes via mean di@erences if the
same measurement scales were used or via standardised mean
di@erences if di@erent measurement scales were used to measure
the same outcome. However, due to the limited amount of data
available for these outcomes, we have presented these outcomes
in a narrative discussion
Unit of analysis issues
We included eight cross-over studies in the review. We analysed
data for the first treatment period from these studies only;
we analysed parallel and cross-over design studies in separate
subgroups.
Dealing with missing data
We sought missing data by contacting the study authors. We carried
out intention-to-treat (ITT), best-case and worst-case analysis on
the primary outcome to account for any missing data (see Data
synthesis). We presented all analyses in the main report.
Assessment of heterogeneity
We assessed clinical heterogeneity by comparing the distribution
of important participant factors between trials (e.g. age,
seizure type, duration of epilepsy, number of AEDs taken at
time of randomisation), and trial factors (e.g. randomisation
concealment, blinding, losses to follow-up). We examined
statistical heterogeneity using a Chi2 test and I2 statistic. When we
found no significant heterogeneity (P < 0.10), we used a fixed-e@ect
model. Had we found heterogeneity (> 50%), we had planned to use
a random-e@ects model for the analysis.
Assessment of reporting biases
We requested protocols for all included studies to enable a
comparison of outcomes of interest. If outcome reporting bias
was suspected for any included study, we had planned to further
investigate using the ORBIT matrix system (Kirkham 2010). We had
planned an examination of asymmetry funnel plots to establish
publication bias, but such an assessment was not possible due to
the small number of studies included in the review.
Data synthesis
We used a fixed-e@ect model meta-analysis to synthesise the data.
We measured the e@ect of each comparison on our preset primary
and secondary outcomes, if data were available. Comparisons we
expected to carry out included:
1. usual treatment plus lamotrigine versus usual treatment plus
placebo;
2. usual treatment plus lamotrigine versus no treatment;
3. usual treatment plus lamotrigine versus usual treatment.
Our preferred estimator for all binary outcomes was the Mantel-
Haenzsel risk ratio (RR). For the outcomes 50% or greater reduction
in seizure frequency and treatment withdrawal, we used 95%
confidence intervals (Cls). For individual adverse e@ects, we used
99% Cls to make an allowance for multiple testing.
Our analyses included all participants in the treatment groups to
which they had been allocated following randomisation.
For the e@icacy outcome (50% or greater reduction in seizure
frequency), we undertook three analyses.
(a) Primary (ITT) analysis
Participants not completing follow-up or with inadequate seizure
data were assumed to be non-responders. To test the e@ect of
this assumption, we undertook the following sensitivity analyses.
Analysis by ITT was done where this was reported by the included
studies.
(b) Worst-case analysis
Participants not completing follow-up or with inadequate seizure
data were assumed to be non-responders in the lamotrigine group,
and responders in the placebo group.
(c) Best-case analysis
Participants not completing follow-up or with inadequate seizure
data were assumed to be responders in the lamotrigine group, and
non-responders in the placebo group.
Subgroup analysis and investigation of heterogeneity
We considered adults and children and doses in our subgroup
analyses. We performed a subgroup analysis for adverse events.
Sensitivity analysis
We intended to carry out sensitivity analyses if peculiarities
were found between study quality, characteristics of participants,
interventions and outcomes.
Summary of findings and assessment of the certainty of the
evidence
We created 'Summary of findings' tables, using GRADEpro and
the GRADE approach for assessing the certainty of evidence
(GRADEpro 2014). We GRADE-assessed the evidence for six of
the outcomes: 50% or greater reduction in seizure frequency;
treatment withdrawal; ataxia; dizziness; fatigue; and nausea.
R E S U L T S
Description of studies
Results of the search
The search carried out on 13 December 2018 identified 27 records
from the databases outlined above. We screened 23 records aMer
duplicates were removed for inclusion in the review. We excluded
16 studies at this point, and requested seven full-text articles
to assess for eligibility. We contacted authors of these trials for
more information, providing their contact details were available.
Following this, we excluded all seven studies (please see Figure 1
and Characteristics of excluded studies for reasons of exclusion).
The latest search (9 March 2020) identified no new, relevant studies.
Thus, no new studies were included in this review.
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Figure 1.   Study flow diagram for 2018 update.
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Figure 1.   (Continued)
 
Included studies
We did not find any new studies for this update.
In a previous version of this review, the review authors included
14 randomised controlled trials that investigated the use of add-
on lamotrigine compared to placebo, in 1806 participants with
uncontrolled focal seizures (38 infants, 199 children, 1569 adults).
Trial characteristics are summarised below. For further information
on each trial, please see Characteristics of included studies.
The 14 studies included five parallel group studies (Baulac 2010;
Duchowny 1999; Matsuo 1993; Naritoku 2007; Schachter 1995); one
parallel group study in infants with a responder-enriched design,
in which all patients received adjunctive lamotrigine during an
open-label phase and those who had a 40% or greater reduction
in the frequency of focal seizures during the last four weeks
were randomly assigned to double-blind treatment for up to eight
weeks with continued lamotrigine or placebo (Piña-Garza 2008);
and eight cross-over studies (Binnie 1989; Boas 1996; Jawad 1989;
Loiseau 1990; Messenheimer 1994; Schapel 1993; Schmidt 1993;
Smith 1993). All but two studies recruited adults; Duchowny 1999
recruited only children, and Piña-Garza 2008 enrolled only infants
aged one to 24 months of age. One trial used extended-release
formulation of lamotrigine (Naritoku 2007), while the other trials
used immediate-release formulations. In general, the individuals
included in these studies had at least three to four focal seizures
a month, despite therapy with a stable antiepileptic drug (AED)
regimen consisting of two or three AEDs, which were appropriate
for the type of epilepsy, and were given in adequate doses.
Almost all studies excluded people with: intellectual disabilities,
progressive neurological disease, major psychiatric problems,
associated pseudo seizures, newly-diagnosed epilepsy, status
epilepticus in the 24 weeks preceding the trial, associated systemic
diseases, abnormal laboratory investigations not explained by
enzyme induction by AEDs, a history of non-compliance, failure to
keep reliable records of seizures or adverse e@ects, irregular clinic
visits, recent use of any other investigational AED, abuse of alcohol
or other prescription or non-prescription drugs; people receiving
chronic medication, especially antipsychotic drugs, women who
were pregnant or at risk of pregnancy, lactating women. For the
cross-over studies, participants were not randomised to a single
dose, but took a range of doses, depending on their clinical
response and the concurrent administration of other AEDs. Use
of valproate was not permitted in three studies (Matsuo 1993;
Messenheimer 1994; Schachter 1995), two excluded people on
valproate monotherapy (Schapel 1993; Smith 1993), while others
used lower dosages of lamotrigine for people on valproate. One
parallel study tested doses of 300 mg and 500 mg of lamotrigine
per day (Matsuo 1993), whereas the others tested a range of doses
between 75 mg and 600 mg per day (median between 200 mg and
400 mg/day). The length of the treatment period varied from eight
to 24 weeks.
All studies were published as full articles, except Schmidt 1993,
which was only published as an abstract. All studies, except Baulac
2010 (which was sponsored by Pfizer Inc), were sponsored by
GlaxoSmithKline, manufacturers of lamotrigine, as part of their pre-
licensing programme.
Excluded studies
In the 2018 update, we excluded seven studies for the following
reasons: one study was not a randomised trial; three studies did not
investigate an eligible population; study results were not available
for one study; and one study was not a placebo-controlled trial. One
study was an ongoing study. The details of these studies are given
in the Characteristics of excluded studies table.
Risk of bias in included studies
See Figure 2 and Figure 3 for a summary of the risk of bias in each
included study. Each study was allocated an overall rating for risk
of bias: low, high, or unclear. See below for specific domain ratings.
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Figure 2.   'Risk of bias' graph: review authors' judgements about each 'Risk of bias' item presented as percentages
across all included studies.
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We rated the method by which allocation was randomised as
having low risk of bias in 11 trials (1243 participants), because they
used a computer-generated randomisation schedule or random
number tables (Binnie 1989; Boas 1996; Duchowny 1999; Jawad
1989; Loiseau 1990; Matsuo 1993; Messenheimer 1994; Schachter
1995; Schapel 1993; Schmidt 1993; Smith 1993). The investigators
did not provide clear methods In three trials (563 participants),
which were rated as unclear (Baulac 2010; Naritoku 2007; Piña-
Garza 2008). For sequence generation, we rated the same 11 studies
as having low risk of bias because they dispensed sequentially
numbered packages to each participant, and random permuted
blocks were used to generate the allocation sequence. We rated
three studies (563 participants) as having unclear risk of bias due to
a lack of details on the methods used (Baulac 2010; Naritoku 2007;
Piña-Garza 2008).
Blinding
We rated four studies (704 participants) as having low risk of
bias for this particular domain because participants, parents and
investigators were blinded (Binnie 1989; Duchowny 1999 ; Loiseau
1990; Schachter 1995). We judged blinding of participants as
unclear in 9 papers (1021 participants) because no details of the
method of blinding were provided (Baulac 2010; Boas 1996; Jawad
1989; Matsuo 1993; Messenheimer 1994; Naritoku 2007; Piña-Garza
2008; Schapel 1993; Schmidt 1993). One study (81 participants) was
rated as high risk of bias because patients and investigators were
able to identify the lamotrigine treatment (Smith 1993).
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Incomplete outcome data
We rated all the included studies (13 studies, 1725 participants),
except one (Smith 1993) , as having low risk of bias for this
domain as there were minimal missing data. Additionally, either ITT
analysis was employed, or there were no concerns of missing data
having an e@ect on the overall outcome estimate. Smith 1993 (81
participants) was rated as unclear risk of bias because participants
who discontinued prematurely did not complete the health-related
quality of life (HRQOL) measure at the time of discontinuation.
Selective reporting
We requested the protocols for all included studies to compare a
priori methods and outcomes to the published report, but none
of the protocols for the included studies were available. We rated
all included studies as low risk of bias for this domain as there
was no suspicion of selective outcome reporting bias. All expected
outcomes were reported in each of the publications.
Other potential sources of bias
We did not detect any other sources of bias across the included
studies, except one (Baulac 2010), because responder rates were
mentioned as percentages and actual numbers were not given.
E:ects of interventions
See: Summary of findings for the main comparison
For the cross-over trials, we analysed data from the first treatment
phase for the e@icacy, treatment, withdrawal, and adverse e@ects.
These data were unpublished and obtained from Glaxo Wellcome,
the sponsors of all but one study (Baulac 2010).
Primary Outcome
Fiy per cent or greater reduction in seizure frequency
A Chi2 test for responses to lamotrigine indicated no significant
heterogeneity between trials (Chi2 = 11.02; df = 11; P = 0.44; I2 = 0%),
so a fixed-e@ect model was used to measure e@icacy.
For 12 studies (1322 participants (adults and children)), the risk
ratio (RR) was 1.80; 95% confidence interval (CI) 1.45 to 2.23
for any dose of lamotrigine added to regular antiepileptic drug
therapy versus placebo. The RR from eight cross-over studies (382
participants) was 2.58; 95% CI 1.44 to 4.61 (Analysis 1.1).
The RR for the worst-case and best-case scenarios were RR 0.97
(95% CI 0.82 to 1.15; Analysis 1.2) and RR 2.88 (95% CI 2.36 to 3.50;
Analysis 1.3), respectively fixed.
The RR for a daily dose of 300 mg of lamotrigine was 1.23; 95% CI
0.57 to 2.67; the RR was 2.13; 95% CI 1.08 to 4.20 for lamotrigine 500
mg per day, compared to placebo (Matsuo 1993). For children, the
RR was 2.64; 95% CI 1.59 to 4.38 (Duchowny 1999) (Analysis 1.1).
We could not calculate responder rates for Schachter 1995 because
baseline seizure counts were not obtained, or for the infants in Piña-




Fourteen studies (1806 participants) were included in this analysis.
The overall RR for treatment withdrawal for any reason was RR
1.11 (95% CI 0.91 to 1.37); thus there was insu@icient evidence
to conclude that participants were more likely to discontinue
lamotrigine than placebo (Analysis 2.1).
We obtained the following data: 136 participants withdrew from
treatment and 77 participants withdrew from control groups in
parallel studies in adults (Baulac 2010, Matsuo 1993, Naritoku 2007,
Schachter 1995); 14 participants withdrew from treatment and
18 from control groups in a parallel study in children (Duchowny
1999); 19 participants withdrew from treatment and 10 participants
withdrew from control groups in cross-over studies in adults (Binnie
1989, Boas 1996, Jawad 1989, Loiseau 1990, Messenheimer 1994,
Schapel 1993, Schmidt 1993, Smith 1993); 11 participants withdrew
from treatment and 16 withdrew from control groups in a parallel
study in infants (Piña-Garza 2008) (Analysis 2.1).
Insu@icient data were available to undertake the planned dose-
response subgroup analyses.
Adverse eects
In addition to reports of ataxia, dizziness, fatigue, and nausea,
some studies reported somnolence, diplopia and headache among
the five most common adverse e@ects and are included in the
analysis. Ataxia, dizziness, diplopia, and nausea were significantly
more likely with lamotrigine. The RR for individual adverse e@ects
were:
1. ataxia - RR 3.34; (99% CI 2.01 to 5.55) (12 studies, 1525
participants, Analysis 3.1);
2. dizziness - RR 2.00 (99% CI 1.52 to 2.64) (13 studies, 1768
participants, Analysis 3.2);
3. fatigue - RR 0.82 (99% CI 0.55 to 1.22) (12 studies, 1552
participants, Analysis 3.3);
4. nausea - RR 1.81(99% CI 1.22 to 2.68) (12 studies, 1486
participants, Analysis 3.4);
5. somnolence - RR 1.39 (99% CI 0.96 to 2.00) (13 studies, 1768
participants, Analysis 3.5);
6. diplopia - RR 3.79 (99% CI 2.15 to 6.68) (3 studies, 944
participants, Analysis 3.6); and
7. headache - RR 1.13 (99% CI 0.88 to 1.45) (5 studies, 1386
participants, Analysis 3.7).
Cognitive eects and quality of life
Two studies incorporated measures of cognitive functions (Banks
1991; Smith 1993 (54 participants)). No significant di@erences were
found on any of the tests used. However, participants receiving
lamotrigine showed a marginal (not significant) reduction in
general cerebral e@iciency as assessed by the third segment of the
Stroop colour word test-a test of concentration and distractibility
(Table 1).
We provided a narrative discussion for this outcome and more
information in Table 1. Meta-analysis of the two studies was not
possible due to the di@erences in cognitive function measured in
the two studies.
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The results of the health-related quality of life (HRQOL)
assessments are given in Table 2. Smith 1993 (54 participants),
incorporated an HRQOL measure containing previously validated
measures of physical, social and psychological functioning and
a novel measure of seizure severity. There were no significant
di@erences for the physical and social components of the HRQOL
measure. Participants also reported significant improvements on
the seizure severity scale when comparing lamotrigine versus
placebo.
We provided a narrative discussion for this outcome and more
information in Table 2. Meta-analysis was not possible as only a
single study reported on this outcome.
D I S C U S S I O N
Summary of main results
Since publication of the previous version of this review, we did not
find any new studies that met the selection criteria for this review.
The baseline phase in all but one trial ranged from four to 12
weeks, the treatment phase from eight to 36 weeks (Schmidt
1993). Eleven of the 14 included trials described adequate methods
of concealment of randomisation, only four described adequate
blinding. All but one trial was sponsored by the manufacturer of
lamotrigine.
This meta-analysis suggested that lamotrigine was more e@ective
than placebo in reducing seizure frequency, when added to
conventionally used antiepileptic drugs (AEDs) in people su@ering
from drug-resistant focal epilepsy. We were unable to examine dose
e@ects in planned subgroup analyses, but the results from Matsuo
1993 suggested increased e@icacy with an increased dose. Only one
study recruited children (Duchowny 1999), and one study recruited
infants (Piña-Garza 2008). We have no evidence from this review
to indicate whether lamotrigine is more or less e@ective in infants
and children than in adults. The use of 50% or greater reduction in
seizure frequency as a measure of e@icacy could be criticised, given
that seizure freedom would be a more relevant clinical measure.
However, seizure freedom is rarely achieved in the studies involving
people with drug-resistant epilepsy.
For a drug to be an attractive option, it would need to have a
favourable adverse-e@ect profile, have little e@ect on cognition,
and have positive e@ects on quality of life, in addition to reducing
seizures. In our review, certain adverse e@ects (ataxia, dizziness,
diplopia, and nausea) were significantly more likely to occur with
lamotrigine. It was emphasised that researchers should routinely
and regularly enquire about adverse e@ects, using a standardised
check-list thesaurus, and should not record only those volunteered
by the patient. More participants had lamotrigine withdrawn than
placebo, but this was not statistically significant.
The results of this review apply only to add-on use of lamotrigine.
Our results do not inform us how add-on lamotrigine compares with
other drugs when used as add-ons. This is an extremely important
issue for clinicians who are faced with an ever-increasing number
of AEDs from which to choose, and who need to make an evidence-
based choice between the AEDs. Indirect comparisons can be
made using results of other reviews, but such indirect comparisons
require cautious interpretation.
Overall completeness and applicability of evidence
Only two studies evaluated the e@ects of add-on lamotrigine
therapy on cognition and quality of life. The results of these studies
suggested that lamotrigine was probably not associated with any
significant cognitive decline. Regardless, the limited data available
and heterogenous measurement scales for quality of life outcome
precluded us from drawing any conclusions about the e@ects of
add-on lamotrigine on cognition and quality of life.
Caution is required when translating the results of clinical trials
into everyday practice. The individuals in trials are a highly
selected population who may be better motivated, and are closely
followed and monitored. Participants who are uncooperative and
non-compliant, who are likely to have adverse e@ects and fewer
benefits, are excluded. The results of this review cannot be
extrapolated to people with generalised epilepsies, about whom
there is a great paucity of data. The safety of lamotrigine during
pregnancy and lactation cannot be ascertained from this review.
The duration of the studies included in this review was insu@icient
to detect changes in cognition, social problems, or long-term
adverse e@ects. Trials that include a larger number of individuals,
preferably who are using lamotrigine as monotherapy, and which
are using reliable, validated measures and longer follow-up are
warranted. This review did not have the sensitivity to detect rare
but serious adverse e@ects, such as psychosis, Steven Johnson's
syndrome, or aplastic anaemia which may be seen with AEDs. Rare
phenomena such as habituation and tolerance may not be evident
in short-term trials. The economic aspects of lamotrigine therapy
also need to be examined.
Certainty of the evidence
Overall, 11 studies were rated as having low risk of bias and three
were judged to have an unclear risk of bias, mainly due to the lack
of information regarding study design. Only four trials reported
e@ective methods for blinding. We rated all the included studies,
except one, as low risk of bias for incomplete outcome data due
to the intention-to-treat (ITT) analyses undertaken by the study
authors.
The GRADE approach was used to rate the certainty of evidence for
each outcome. The assessments are presented in a 'Summary of
findings' table (see Summary of findings for the main comparison).
Importantly, we judged that it was not necessary to downgrade for
risk of bias because, as stated above, the majority of the included
studies were at low risk of bias. For the main outcome of 50% or
greater reduction in seizure frequency, the certainty of evidence
was rated as moderate (all studies contributed to the analysis).
Notably, the evidence for the main outcome was downgraded once
from high certainty due to the limited number of events reported.
Tolerability outcomes (withdrawal and adverse e@ects) were
judged as high to moderate certainty. Again, this was largely
due to the number of events reported being insu@icient to
draw conclusions. Only one outcome, the number of participants
experiencing dizziness, was downgraded due to inconsistency aMer
significant statistical heterogeneity was detected in the data set.
The evidence for two of the outcomes, ataxia and diplopia, was
upgraded back to high certainty because the risk ratio estimated
exceeded 2.00, indicating a large e@ect size.
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Potential biases in the review process
Although all protocols were requested, the time frame in which
the majority of the studies were conducted made retrieval of all of
these di@icult. This could lead to potential bias through omitted
information to which we did not have access. All studies but
one were sponsored by GlaxoSmithKline, the manufacturers of
lamotrigine and this could be a potential source of bias.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
In people with drug-resistant focal epilepsy, lamotrigine when
used as an add-on treatment was e@ective in reducing the seizure
frequency. The lowest daily dose tested in the trials included in this
review was 75 mg for people on sodium valproate monotherapy,
100 mg in the balanced group receiving enzyme inducing AEDs and
valproate, and 200 mg in people receiving enzyme inducing AEDs.
However, the trials reviewed were of relatively short duration.
Implications for research
Further evaluation of lamotrigine is required to assess the following
e@ects in the long term:
1. e@ects on seizures;
2. adverse e@ects;
3. e@ects on cognition;
4. e@ects on quality of life;
5. health economic e@ects.
In the following scenarios:
1. lamotrigine compared to other add-on treatments in drug-
resistant focal epilepsy;
2. lamotrigine for childhood and generalised epilepsies;
3. lamotrigine compared with standard AEDs such as:
a. lamotrigine as monotherapy in focal epilepsy;
b. lamotrigine as monotherapy in generalised epilepsy.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Double-blind, placebo-controlled, randomised, parallel-group study.
Three arms: 1 placebo, 1 lamotrigine, and 1 pregabalin.
Baseline period = 6 weeks; double-blind treatment period = 17 weeks, which included initial 5 weeks
dosage titration for lamotrigine and 6 weeks maintenance at 300 mg/day and additional treatment pe-
riod of 6 weeks with dose escalation to 400 mg/day for those with continuing seizures. Double-blind
treatment period was followed by an open-label study or a 2-week taper phase.
Participants 97 centres in Europe, Canada, and Australia.
Adults over the age of 18 years and body weight ≥40 kg, with a diagnosis of focal seizures (as defined by
the International League Against Epilepsy Classification of Seizures).
546 persons screened, 434 randomised.
M:F ratio 39.3:60.7 for placebo and 54.6:45.4 for lamotrigine.
Mean age (years) 39.1 in placebo group and 39.4 in lamotrigine group.
Minimum seizure frequency of 4 focal seizures during the 6-week baseline period and no 28-day period
free of focal seizure, despite treatment with at least three AEDs from at least two different AED classes,
each at or above the lowest recommended dose or the lowest adequate plasma concentration given
for a minimum of 3 months; were allowed to take one to three AEDs concurrently, one of which had to
be an enzyme inducer.
Exclusion Criteria:
1. previous treatment with pregabalin;
2. previous treatment with lamotrigine within 6 months before entering baseline;
3. history of rash with lamotrigine;
4. previous treatment with valproic acid products within 2 months of baseline; and
5. previous treatment with gabapentin, felbamate, or vigabatrin < 6 weeks prior to screening.
6. history of status epilepticus in the last 1 year, significant psychiatric disorder, or use of concomitant
medication that could interfere with response to study medications or affect seizure frequency.
7. pregnant or planning to conceive, lactation.
Interventions Group I (n = 141): received placebo.
Group II (n = 141): received lamotrigine 300 mg/day after dose titration over 5 weeks, and if seizures oc-
curred during 6-week maintenance, further dose escalation to 400 mg/day from week 12 to 17.
Group III (n = 152): received pregabalin. The participants randomised to pregabalin were not included
in this review.
Outcomes 1. Seizure frequency.
2. Adverse events, including changes in physical and neurologic examinations, 12-lead electrocardio-
grams (ECGs), and clinical laboratory tests (haematology, blood chemistry, pregnancy, and urinaly-
sis).
Notes This study was sponsored by Pfizer Inc.
Risk of bias
Bias Authors' judgement Support for judgement
Baulac 2010 
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Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not specified.
Allocation concealment
(selection bias)
Unclear risk The details were not mentioned in the publication.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details provided regarding blinding of participants, study personnel, and
outcome assessors.
Regarding the medications, blinding was maintained by administering the
same numbers of capsules per day per group.
Incomplete outcome data
(attrition bias)
Low risk 35 withdrew from placebo group and 40 from lamotrigine group. The reasons
for exclusion were reported.
Selective reporting (re-
porting bias)
Low risk Protocol unavailable to check a priori outcomes, but appears all expected and
pre-specified outcomes are reported.
Other bias Unclear risk Responder rates were mentioned as percentages and actual numbers were not
given. Author has been contacted regarding actual number of responders in




Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, and 1 lamotrigine.
Baseline period = 8 weeks.Treatment I and II = 12 weeks each. Washout = 6 weeks, including taper peri-
od.
Participants Single-centre study from the Netherlands.
34 adults aged between 16 to 51 years (mean 37.1 +/- 10.26).
16 were randomised to lamotrigine and 18 to placebo during the first treatment phase.
All had drug-resistant focal seizures.
The age of onset of epilepsy ranged from 1 to 40 years (mean 14.3 +/- 10.7), the duration of epilepsy was
6 to 49.5 (mean 22.8 +/- 11) years.
Maximum number of other AEDs = 4.
Interventions Add-on lamotrigine, or placebo. Median daily dose of lamotrigine was 200 mg. Participants on val-
proate received lower doses.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Binnie 1989 
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Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Participants were allocated sequentially-numbered sealed packages contain-
ing either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Participants and parents were blinded. An unblinded investigator with knowl-
edge of the medication and plasma concentrations instructed the blinded in-
vestigators about dispensing the trial medications.
Identical tablets and packaging used.
Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. No participant withdrew from
the study during the first treatment phase.
Selective reporting (re-
porting bias)
Low risk All outcomes stated in methods section of paper were reported in the results.
There was no protocol available to check to priori outcomes.




Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Five phases: baseline period = 12 weeks; treatment I = 12 weeks; washout I = 4 weeks; treatment II = 12
weeks; washout II = 4 weeks.
Participants 4-centre study from Denmark.
56 adults with drug-resistant focal seizures, aged from 16 to 65 years.
30 were allocated to lamotrigine and 26 to placebo during the first treatment phase.
There were 27 men and 29 women.
Maximum number of other AEDs = 3.
Interventions Lamotrigine or placebo was added to the patients' existing AEDs. The dose of lamotrigine varied from
75 mg to 400 mg. Participants on valproate received lower doses.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Partcipants were allocated sequentially-numbered, sealed packages contain-
ing either lamotrigine or placebo.
Boas 1996 
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Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details provided regarding blinding of participants, study personnel, and
outcome assessors.
All treatments (tablets) and packaging were identical. Prepacked coded med-
ication was dispensed by pharmacy.
Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. 10 participants withdrew from




Low risk All outcomes stated in methods section of paper were reported in the results.
There was no protocol available to check a priori outcomes.




Methods Randomised, double-blind, parallel group, multi-centre study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Pre-randomisation baseline period = 8 weeks. Treatment phase = 18 weeks (including 6-week titra-
tion). Taper and follow-up = 1 to 6 weeks, including 1-week taper.
Participants 40 centres from USA and France:
199 children with drug-resistant focal seizures, aged from 2 to 16 years (27% were less than 6 years old,
60% aged between 6 to 12 years and 11% were over 12 years age).
98 were allocated to lamotrigine and 101 to placebo.
There were 103 boys and 96 girls.
Maximum number of other AEDs = 2.
Interventions Add-on lamotrigine or placebo. Median dose ranged from 2.7 mg/kg/day to 12.9 mg/kg/day depending
upon concurrent use of other AEDs. Participants on valproate received lower doses.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Patients were randomised with a blocked randomisation scheme to treatment
with add-on lamotrigine or matched placebo in bottles labelled with pre-gen-
erated participant numbers.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Treatment assignments were unknown to all study-site personnel, patients
and sponsors. Lamotrigine and matching placebo were provided as berry-
Duchowny 1999 
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Low risk No participants were excluded from analysis. 2 enrolled participants withdrew
before randomisation. 14 participants allocated to lamotrigine and 18 partici-




Low risk All outcomes stated in methods section of paper were reported in the results.
There was no protocol available to check a priori outcomes.




Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Five phases: baseline period = 8 weeks; Treatment I = 12 weeks; Washout I = 6 weeks; treatment II = 12
weeks; Washout II = 6 weeks.
Participants Single-centre study from UK.
24 adults with drug-resistant focal seizures, aged between 16 to 60 years.
12 were allocated to lamotrigine and 12 to placebo in the first treatment phase.
Maximum number of other AEDs = 2.
Interventions Add-on lamotrigine or placebo. The median daily dose of lamotrigine was 250 mg. Participants on val-
proate received lower doses. Unblinded investigator wrote prescriptions based on plasma concentra-
tion.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Partcipants were allocated by sequentially numbered, sealed packages con-
taining either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details provided regarding blinding of participants, study personnel, and
outcome assessors.
Identical tablets and packaging used.
Jawad 1989 
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Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. One participant who was allo-
cated to lamotrigine withdrew from the study (the reason for exclusion was re-
ported) and none withdrew from the placebo group.
Selective reporting (re-
porting bias)
Low risk All outcomes stated in methods section of paper were reported in the results.
There was no protocol available to check a priori outcomes.




Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Five phases: Pre-randomisation baseline = 4 weeks. Treatment I = 8 weeks. Washout I = 4 weeks. Treat-
ment II = 8 weeks. Washout II = 4 weeks.
Participants Single-centre study from France.
25 adults, aged between 20 to 54 (years mean 34.2 +/- 12.41) years.
All had drug-resistant focal epilepsy.
11 were randomised to lamotrigine and 14 to placebo in the first treatment phase.
The duration of epilepsy ranged from 3 to 45 years (mean 17.4 +/- 10.81).
Maximum number of other AEDs = 2.
Interventions Add-on lamotrigine or placebo. The median daily lamotrigine dose was 300 mg. Participants on val-
proate received lower doses.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Participants were allocated by sequentially numbered, sealed packages con-
taining either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Neurologists, participants and parents were blinded. Investigators were blind-
ed.
All treatments (tablets) and packaging were identical. Pre-packed coded med-
ication dispensed by pharmacy.
Loiseau 1990 
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Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. 2 participants withdrew from the




Low risk All outcomes stated in methods section of paper were reported in the results.
There was no protocol available to check a priori outcomes.




Methods Randomised, double-blind, parallel group, multi-centre study.
Three treatment arms: 1 placebo, 1 lamotrigine 300 mg and 1 lamotrigine 500 mg.
Pre-randomisation baseline = 12 weeks. Treatment phase = 24 weeks. Taper and follow-up = 3 weeks.
Participants Multi-centre US study with 216 participants (67 males and 149 females) with a mean age of 33 (range 18
to 63) years. All had drug-resistant focal epilepsy.
73 were randomised to receive placebo, while 71 received lamotrigine 300 mg per day and 72 received
lamotrigine 500 mg per day.
The mean duration of epilepsy was 21.9 years and the mean age at onset 11 years.
Maximum number of other AEDs = 3. People receiving valproate were excluded.
Interventions Add-on lamotrigine 300 mg or lamotrigine 500 mg or placebo.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Randomisation concealment: allocated sequentially numbered, sealed pack-
ages containing either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details provided regarding blinding of participants, study personnel, and
outcome assessors.
Identical tablets and packaging used.
Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. 25 participants withdrew from
the study; 7 receiving lamotrigine 300 mg, 12 receiving lamotrigine 500 mg and
6 receiving placebo. The reasons for exclusion were reported.
Selective reporting (re-
porting bias)
Low risk Protocol unavailable to check a priori outcomes, but appears all expected and
pre-specified outcomes were reported.
Matsuo 1993 
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Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Total study duration was 43 weeks. Pre-randomisation baseline = 8 weeks. Treatment A = 14 weeks (in-
cluding 2 weeks blinded tapering). Follow-up period = 3 weeks. Treatment B = 14 weeks (including 2
weeks blinded tapering). Washout = 4 weeks.
Participants Multi-centre US study with 98 participants (46 men and 52 women) with drug-resistant focal epilepsy.
46 were randomised to receive lamotrigine and 52 to placebo in the first treatment phase.
Age range 18 to 64 years with a mean of 35.
Age at onset of epilepsy was 12 years; mean duration 23.1 years.
Up to 3 other AEDs were permitted. Concomitant use of valproate was not allowed.
Interventions Add-on lamotrigine or placebo. Median lamotrigine dose 400 mg/day.
Outcomes 1. 50% responder rates
2. Withdrawal from study for any reason.
3. Adverse effects
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Participants were allocated by sequentially-numbered, sealed packages con-
taining either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk Investigators were blinded. No more information provided regarding blinding
of neurologists, participants, and parents.
All treatments (tablets) and packaging were identical. Pre-packed coded med-
ication dispensed by pharmacy.
Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. 6 participants withdrew from the




Low risk All outcomes stated in methods section of paper were reported in the results.
There was no protocol available to check a priori outcomes.
Other bias Low risk None detected.
Messenheimer 1994 
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Methods Double-blind, randomised, parallel-group, placebo-controlled multi-centre global study.
Screening phase of up to 2 weeks during which eligibility was determined; an 8-week baseline phase
serving to exclude from randomisation patients who did not meet the minimum seizure frequency cri-
terion; a 7-week, double-blind escalation phase during which lamotrigine XR (Extended Release) was
introduced and titrated to its target dose; and a 12-week, double-blind maintenance phase during
which dosage of study medication and concomitant AED were maintained.
Participants International multi-centre study from North and South America, Europe, and Asia.
Uncontrolled focal seizures (at least 8 focal seizures in 8 weeks with at least one focal seizure during
each 4-week period of the baseline phase).
Male and female patients 12 years of age or older with focal seizures with or without generalisation
who were treated with a stable regimen of one or two AEDs for at least 4 weeks before starting the
baseline phase.
Total number enrolled = 244; (121 to treatment arm; 123 to placebo arm);
93% were aged between 16 and 65 years; mean age in lamotrigine group = 35.8 (12.7) and in placebo
group = 37.5 (14.4) years.
Males constituted 47% of participants in lamotrigine group and 53% of participants in placebo group.
Exclusion criteria included:
1. presence of primary generalised seizures,
2. status epilepticus during or within 24 weeks before the start of the baseline phase,
3. chronic treatment with three or more AEDs,
4. current or previous use of lamotrigine,
5. current use of felbamate or adherence to a ketogenic diet,
6. pregnancy or planned pregnancy during the study or within 3 weeks after the last dose of study med-
ication.
Interventions Treatment group received lamotrigine XR (Extended Release); other group received identical placebo.
Dosage of lamotrigine XR was escalated gradually up to 200 mg/day in those receiving valproate, 300
mg/day in those receiving valproate and an enzyme inducing AED, and up to 500 mg/day in those re-
ceiving enzyme inducing AEDs without valproate.
Outcomes 1. Seizure frequency.
2. Adverse events
3. Withdrawals from study.
4. US participants had following additional assessments: Profile of Mood States (POMS), Center for Epi-
demiologic Studies-Depression Scale (CES-D), research version of the Neurological Disorders Depres-
sion Inventory-Epilepsy (NDDI-E), Quality of Life in Epilepsy-31-P (QOLIE-31-P), Liverpool Adverse Ex-
perience Profile (AEP), Seizure Severity Questionnaire (SSQ), and Epworth Sleepiness Scale (ESS).
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not specified.
Naritoku 2007 
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Allocation concealment
(selection bias)
Unclear risk Details not reported in the publication.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No information provided.
Incomplete outcome data
(attrition bias)
Low risk 24 participants withdrew from treatment group and 16 from placebo group.
The reasons for exclusion were reported.
Selective reporting (re-
porting bias)
Low risk There was no protocol available to check a priori outcomes,but appears all ex-
pected and pre-specified outcomes were reported.




Methods Randomised, double-blind, multi-centre placebo-controlled trial.
Responder-enriched design in which all patients received adjunctive lamotrigine during an open-label
phase (wherein dose was escalated to achieve optimal response); those who had a 40% or greater re-
duction in the frequency of focal seizures during the last 4 weeks of the optimisation period were ran-
domly assigned to double-blind treatment for up to 8 weeks with continued lamotrigine or placebo.
Participants Total number enrolled = 38. Male or female infants aged 1 month to 24 months with at least 4 focal
seizures (with or without generalisation) per month, uncontrolled by 1 AED and who showed 40% or
greater reduction in seizure frequency during an initial open label phase.
There were 19 participants in each arm;
median age was 13.5 months in lamotrigine arm and 14.2 months in placebo arm; median age of onset
of epilepsy was 3 months and median duration of epilepsy was 9.1 months in lamotrigine arm and 8.5
months in placebo arm.
Exclusion Criteria: participants with progressive myoclonic epilepsy; progressive neurologic disease,
seizures unrelated to epilepsy or resulting from drug withdrawal; use of felbamate, adrenocorticotrop-
ic hormone, previous use of lamotrigine, two AEDs as maintenance treatment, presence of hepatic dys-
function, having a functioning vagus nerve stimulator; or being on a ketogenic diet.
Interventions Intervention group was continued on lamotrigine. Control group participants had their lamotrigine
dose tapered and changed to placebo. The maximum maintenance dose was 5.1 mg/kg/day for those
on non–enzyme-inducing AEDs or valproate and 15.6 mg/kg/day for those on enzyme-inducing AEDs.
Outcomes 1. Percentage of patients who had treatment failures during the double-blind phase.
2. Cumulative percentage of patients who met escape criteria as a function of days on double-blind study
medication.
Participants were withdrawn from study if they met one of the following criteria:
1. 50% increase in monthly focal seizure frequency compared with seizure frequency during the last 4
weeks of the open-label optimisation period;
2. a doubling of the highest consecutive 2-day focal seizure count observed during the open-label opti-
misation period;
3. onset of a new and more severe seizure type;
4. clinically significant worsening of non-focal seizures that were also observed during the historical
baseline phase or the open-label optimisation period;
5. the need to use any therapeutic intervention in addition to study medication to control seizures; or
Piña-Garza 2008 
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6. status epilepticus.
Notes The protocol was amended midway through the study to randomly assign all patients with at least 40%
reduction in seizure frequency, instead of planned inclusion of participants with 40% to 80% reduction
in seizure frequency. 43 subjects who had more than 80% reduction in seizure frequency before the
protocol amendment were not included in the double-blind study.
This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Method of randomisation not specified.
Allocation concealment
(selection bias)
Unclear risk Details not reported in the publication.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No information provided.
Incomplete outcome data
(attrition bias)
Low risk 11 patients (8 in the lamotrigine group and 3 in placebo group) completed the
double-blind phase, 25 (9 in the lamotrigine group and 16 in placebo group)
met escape criteria, and 2 (both in the lamotrigine group) prematurely with-
drew because of protocol violations. The reasons for exclusion were reported.
Selective reporting (re-
porting bias)
Low risk All expected and pre-specified outcomes were reported. Protocol was not
available.




Methods Randomised, double-blind, parallel-group study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Patients were randomised to lamotrigine or placebo in a ratio of 3:1.
Pre-randomisation baseline = 4 weeks. Treatment phase = 24 weeks. Taper and follow-up = 3 weeks.
Participants A 34-centre US study with 446 participants with drug-resistant focal seizures:
334 were randomised to lamotrigine and 112 to placebo.
There were 236 men and 210 women.
The mean age was 35 years (range 18 to 64).
The mean duration of epilepsy was 21 years, median age at onset: 12 years in the lamotrigine group
and 11.5 in the placebo group.
Maximum number of other AEDs = 3.
Concomitant valproate therapy was not permitted.
Interventions Add-on lamotrigine or placebo.
Lamotrigine dose up to 500 mg/day.
Schachter 1995 
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Outcomes 1. Withdrawals from treatment.
2. Adverse effects.
Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Participants were allocated by sequentially numbered, sealed packages con-
taining either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Low risk Neurologists, participants and parents were blinded. Investigators were blind-
ed.
Identical tablets and packaging used.
Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. 73 participants withdrew from




Low risk All outcomes stated in methods section of paper were reported in the results.
There was no protocol available to check a priori outcomes.




Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Pre-randomisation baseline = 12 weeks. Treatment I and II = 12 weeks each. Washout I and II = 4 weeks
each, including 1 week taper.
Participants Multi-centre Australian study.
41 participants (21 males and 20 females) with drug-resistant focal seizures
20 were randomised to receive placebo and 21 to lamotrigine.
The age ranged from 17 to 63 (median 28) years. The mean age at onset was 10.4 +/-9.6 years.
Maximum number of other AEDs permitted = 3.
People receiving valproate monotherapy were excluded.
Interventions Add-on lamotrigine or placebo. Median daily dose of lamotrigine was 300 mg. Participants receiving
valproate received lower doses.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Schapel 1993 
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Notes Banks 1991 is linked to this study and investigated cognitive functions: i) concentration and attention;
ii) general cerebral efficiency; and iii) mnestic functions (immediate, short term and new learning abili-
ty).
This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Participants were allocated by sequentially numbered, sealed packages con-
taining either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details provided regarding blinding of participants, study personnel, and
outcome assessors.




Low risk No participants were excluded from analysis. None withdrew from the study.
Selective reporting (re-
porting bias)
Low risk Protocol unavailable, but appears all expected and pre-specified outcomes
were reported.




Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Pre-randomisation baseline not known. Treatment I and II = 12 weeks each, including 2-week tapering
period.
Washout = 2 weeks .
Participants Single-centre German study.
23 adults (11 men and 12 women) with drug-resistant focal seizures.
11 were randomised to receive lamotrigine and 12 to placebo in the initial treatment phase.
Age of participants ranged from 16 to 62 years.
Maximum number of other AEDs permitted was 2.
Interventions Add-on lamotrigine or placebo. Dosage varied from 50 mg to 450 mg (median dose was 300 mg).
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
Schmidt 1993 
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Notes This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Participants were allocated by sequentially numbered, sealed packages con-
taining either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
Unclear risk No details provided regarding blinding of participants and parents. Unblinded
investigator wrote prescriptions based on plasma concentration.
Identical tablets and packaging were used.
Incomplete outcome data
(attrition bias)
Low risk No participants were excluded from analysis. 1 participant receiving lamotrig-




Low risk Protocol unavailable, but appears all expected and pre-specified outcomes
were reported.




Methods Randomised, double-blind, cross-over study.
Two treatment arms: 1 placebo, 1 lamotrigine.
Pre-randomisation baseline = 4 weeks. Treatment I and II = 18 weeks each. Washout = 6 weeks.
Participants Single-centre UK study.
81 participants with drug-resistant focal epilepsy (33 men and 48 women).
41 were randomised to lamotrigine and 40 to placebo in the initial treatment phase.
The age range was 15 to 67 years (mean 33.7);
duration of epilepsy ranged from 4 to 45 years (mean 21).
The mean age at onset was 11.8 years (< 1 to 52 years).
Maximum number of other AEDS permitted was 2.
Interventions Add-on lamotrigine or placebo. Lamotrigine dose up to 400 mg/day. Median daily dose was 300 mg.
Participants on valproate received lower doses.
Outcomes 1. 50% responder rates.
2. Withdrawal from study for any reason.
3. Adverse effects.
4. Health-related quality of life (HRQL).
Notes HRQL model was completed by 40 to 54 of 81 participants.
Smith 1993 
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This study was sponsored by GlaxoSmithKline, the manufacturer of LTG.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated random permuted blocks.
Allocation concealment
(selection bias)
Low risk Partecipants were allocated sequentially numbered, sealed packages contain-
ing either lamotrigine or placebo.
Blinding (performance
bias and detection bias) 
All outcomes
High risk Patients (46/73) and investigators (52/73) were able to identify lamotrigine
treatment.




Unclear risk No participants were excluded from analysis. 9 people withdrew from the
study; 6 receiving lamotrigine and 3 receiving placebo. The reasons for exclu-
sion were reported.
Patients who discontinued prematurely did not complete the HRQOL measure
at the time of discontinuation, the exclusion of treatment failures may intro-
duce a bias in favour of lamotrigine.
Selective reporting (re-
porting bias)
Low risk Protocol unavailable, but appears all expected and pre-specified outcomes
were reported.
Other bias Low risk None detected.
Smith 1993  (Continued)
AED: antiepileptic drug; LTG: lamotrigine; HRQOL: Health-Related Quality of Life
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Berg 2015 Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.
Berg 2017 Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.
Biton 2010 Ineligible population: participants included had primary generalised epilepsy and not focal
seizures.
Biton 2013 Inelegible population: participants included in the study had uncontrolled focal epilepsy and gen-
eralised tonic-clonic seizures.
Brzakovic 2012 Inelegible population: participants included in the study had uncontrolled focal epilepsy and gen-
eralised tonic-clonic seizures.
Carignani 2004 Published as conference abstract: details of the methods and results are not available.
Carignani 2006 Published as conference abstract: details of the methods and results are not available.
Chung 2009 Comparative study among lamotrigine and topiramate. Not placebo controlled.
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Study Reason for exclusion
Contin 2016 Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.
Cramer 2013 Not a randomised controlled trial.
French 2012 Not a randomised controlled trial.
Frith 2015 Inelegible population: participants included in the study did not have drug-resistant epilepsy.
Girolineto 2012 Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.
Hammer 2008 Published as conference abstract: details of the methods and results are not available.
Hartung 2012 Inelegible population: participants included in the study had epilepsy, migraine, pain, psychiatric
disorders.
Helmstaedter 2013 Participants included in the study had all epileptic types. Lacosamide as add-on for epilepsy and in
comparison with lamotrigine and topiramate.
IRCT2013021211560N3 2013 Inelegible population: participants included in the study did not have drug-resistant epilepsy.
Kang 2012 Inelegible population: participants included in the study had all epileptic types.
Lee 2018 Inelegible population: participants included in the study had all epileptic types.
Mintzer 2018 Not randomised controlled trial: it is a post-hoc analyses.
Montouris 2007 Published as conference abstract: details of the methods and results are not available.
NCT00208520 Inelegible population: participants included in the study did not have drug-resistant epilepsy.
NCT00292461 Details of the methods and results are not available.
NCT00807989 Details of the methods and results are not available.
NCT01891890 Details of the methods and results are not available.
NCT02100644 Not a randomised controlled trial.
NCT02429596 Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.
Ohtahara 2008 Comparative study of lamotrigine and zonisamide. Not placebo controlled.
Premoli 2017 No types of outcome measures.
Privitera 2016 Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.
Sander 1990 Study of institutionalised people with severe epilepsy. Participants included in the study had all
epileptic types.
Semah 2014 No lamotrigine in add-on.
Sethi 2002 Inelegible population: participants included in the study did not have drug-resistant epilepsy.
Shinnar 2015 Ineligible population: participants included had primary generalised epilepsy and not focal
seizures.
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Study Reason for exclusion
Stolarek 1994 Details of the results are not available.
Thangaratinam 2018 Inelegible population: participants included in the study had all epileptic types.
Ting 2015 Comparative study among therapeutic equivalents of lamotrigine. Not placebo controlled.
Tomson 2012 Published as conference abstract: details of the methods and results are not available.
Tomson 2013 Not a randomised controlled trial.
Veendrick-Meekes 2000 Published as conference abstract: details of the methods and results are not available.
Wu 2018 Inelegible population: participants included in the study had all epileptic types.
Yamamoto 2012 Not a randomised controlled trial.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Efficacy and Tolerability of Low vs. Standard Daily Doses of Antiepileptic Drugs in Newly Diagnosed,
Previously Untreated Epilepsy (STANDLOW).
Methods Multicenter, Randomized, Single-blind, Parallel-group trial.
Participants Age 18 years or older; focal untreated epilepsy.
Interventions Low vs Standard dose lamotrigine.
Outcomes Primary Outcome Measures: Treatment failure [Time Frame: 12 months ]The proportion of patients
experiencing a treatment failure motivated by the need to change the assigned dose or the as-
signed drug for seizure relapse during the follow-up.
Secondary Outcome Measures: 1. Drug-related adverse events [ Time Frame: 12 months ]the pro-
portion of patients experiencing a treatment failure motivated by intolerable drug-related adverse
events during the follow-up; 2. Quality of life in epilepsy scale 31 items(QOLIE-31), italian version
[ Time Frame: 12 months ]QOLIE-31 total score at baseline and last visit. Maximum total score is 100
(best quality of life possible) and the minimum is 0 (worst quality of life possible). 3. Patients health
care's satisfaction (PSQ-18) scale, 18 items [ Time Frame: 12 months ]The score of the seven PSQ-18
subscales (general satisfaction, technical quality, interpersonal manner, communication, financial
aspects, time spent with doctor, accessibility and convenience) at baseline and last visit. Possible
scores of each subscale range from 1 (worst satisfaction) to 5 (better satisfaction). There is no total
score for this scale. 4. Health care resources utilization. [ Time Frame: 12 months ]The mean daily
patient's cost of health care resources consumed for the management of epilepsy during the first
12 months of the study.
Starting date September 2018
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D A T A   A N D   A N A L Y S E S
 
Comparison 1.   E:icacy of add-on lamotrigine versus placebo - 50% responders





Statistical method Effect size
1 Intention-to-treat analysis 12   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Cross-over studies 8 382 Risk Ratio (M-H, Fixed, 95% CI) 2.58 [1.44, 4.61]
1.2 Parallel group lamotrigine -
300 mg
1 144 Risk Ratio (M-H, Fixed, 95% CI) 1.23 [0.57, 2.67]
1.3 Parallel group lamotrigine -
500 mg
1 145 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [1.08, 4.20]
1.4 Parallel group (children) 1 199 Risk Ratio (M-H, Fixed, 95% CI) 2.64 [1.59, 4.38]
1.5 Parallel group - Adults - lam-
otrigine ER
1 243 Risk Ratio (M-H, Fixed, 95% CI) 1.70 [1.16, 2.50]
1.6 Parallel group 300 mg to 600
mg
1 282 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.74, 1.75]
1.7 Any dose lamotrigine, adults
or children
12 1322 Risk Ratio (M-H, Fixed, 95% CI) 1.80 [1.45, 2.23]
2 Worst-case scenario 12 1322 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.82, 1.15]
3 Best-case scenario 12 1322 Risk Ratio (M-H, Fixed, 95% CI) 2.88 [2.36, 3.50]
 
 
Analysis 1.1.   Comparison 1 E:icacy of add-on lamotrigine versus
placebo - 50% responders, Outcome 1 Intention-to-treat analysis.
Study or subgroup Favours
Placebo
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 Cross-over studies  
Binnie 1989 1/16 1/18 6.82% 1.13[0.08,16.55]
Boas 1996 6/30 4/26 31.04% 1.3[0.41,4.11]
Jawad 1989 6/12 1/12 7.24% 6[0.85,42.59]
Loiseau 1990 2/11 1/14 6.37% 2.55[0.26,24.56]
Messenheimer 1994 10/46 4/52 27.2% 2.83[0.95,8.4]
Schapel 1993 5/20 1/21 7.07% 5.25[0.67,41.1]
Schmidt 1993 1/11 1/12 6.93% 1.09[0.08,15.41]
Smith 1993 4/41 1/40 7.33% 3.9[0.46,33.42]
Subtotal (95% CI) 187 195 100% 2.58[1.44,4.61]
Total events: 35 (Favours Placebo), 14 (Placebo)  
Heterogeneity: Tau2=0; Chi2=3.47, df=7(P=0.84); I2=0%  
Test for overall effect: Z=3.19(P=0)  
   
Favours Placebo 100.1 50.2 20.5 1 Favours Lamotrigine
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Study or subgroup Favours
Placebo
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.2 Parallel group lamotrigine - 300 mg  
Matsuo 1993 12/71 10/73 100% 1.23[0.57,2.67]
Subtotal (95% CI) 71 73 100% 1.23[0.57,2.67]
Total events: 12 (Favours Placebo), 10 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.53(P=0.59)  
   
1.1.3 Parallel group lamotrigine - 500 mg  
Matsuo 1993 21/72 10/73 100% 2.13[1.08,4.2]
Subtotal (95% CI) 72 73 100% 2.13[1.08,4.2]
Total events: 21 (Favours Placebo), 10 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.18(P=0.03)  
   
1.1.4 Parallel group (children)  
Duchowny 1999 41/98 16/101 100% 2.64[1.59,4.38]
Subtotal (95% CI) 98 101 100% 2.64[1.59,4.38]
Total events: 41 (Favours Placebo), 16 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.76(P=0)  
   
1.1.5 Parallel group - Adults - lamotrigine ER  
Naritoku 2007 49/121 29/122 100% 1.7[1.16,2.5]
Subtotal (95% CI) 121 122 100% 1.7[1.16,2.5]
Total events: 49 (Favours Placebo), 29 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.72(P=0.01)  
   
1.1.6 Parallel group 300 mg to 600 mg  
Baulac 2010 34/141 30/141 100% 1.13[0.74,1.75]
Subtotal (95% CI) 141 141 100% 1.13[0.74,1.75]
Total events: 34 (Favours Placebo), 30 (Placebo)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.57(P=0.57)  
   
1.1.7 Any dose lamotrigine, adults or children  
Baulac 2010 34/141 30/141 29.5% 1.13[0.74,1.75]
Binnie 1989 1/16 1/18 0.93% 1.13[0.08,16.55]
Boas 1996 6/30 4/26 4.21% 1.3[0.41,4.11]
Duchowny 1999 41/98 16/101 15.5% 2.64[1.59,4.38]
Jawad 1989 6/12 1/12 0.98% 6[0.85,42.59]
Loiseau 1990 2/11 1/14 0.87% 2.55[0.26,24.56]
Matsuo 1993 33/143 10/73 13.02% 1.68[0.88,3.22]
Messenheimer 1994 10/46 4/52 3.69% 2.83[0.95,8.4]
Naritoku 2007 49/121 29/122 28.4% 1.7[1.16,2.5]
Schapel 1993 5/20 1/21 0.96% 5.25[0.67,41.1]
Schmidt 1993 1/11 1/12 0.94% 1.09[0.08,15.41]
Smith 1993 4/41 1/40 1% 3.9[0.46,33.42]
Subtotal (95% CI) 690 632 100% 1.8[1.45,2.23]
Total events: 192 (Favours Placebo), 99 (Placebo)  
Heterogeneity: Tau2=0; Chi2=11.02, df=11(P=0.44); I2=0.14%  
Favours Placebo 100.1 50.2 20.5 1 Favours Lamotrigine
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Study or subgroup Favours
Placebo
Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Test for overall effect: Z=5.34(P<0.0001)  
Favours Placebo 100.1 50.2 20.5 1 Favours Lamotrigine
 
 
Analysis 1.2.   Comparison 1 E:icacy of add-on lamotrigine versus
placebo - 50% responders, Outcome 2 Worst-case scenario.
Study or subgroup Lamotrigine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Baulac 2010 34/141 65/141 34.55% 0.52[0.37,0.74]
Binnie 1989 1/16 1/18 0.5% 1.13[0.08,16.55]
Boas 1996 6/30 6/26 3.42% 0.87[0.32,2.36]
Duchowny 1999 41/98 34/101 17.8% 1.24[0.87,1.78]
Jawad 1989 6/12 1/12 0.53% 6[0.85,42.59]
Loiseau 1990 2/11 2/14 0.94% 1.27[0.21,7.65]
Matsuo 1993 33/143 16/73 11.26% 1.05[0.62,1.78]
Messenheimer 1994 10/46 8/52 3.99% 1.41[0.61,3.28]
Naritoku 2007 49/121 45/122 23.82% 1.1[0.8,1.51]
Schapel 1993 5/20 1/21 0.52% 5.25[0.67,41.1]
Schmidt 1993 1/11 1/12 0.51% 1.09[0.08,15.41]
Smith 1993 4/41 4/40 2.15% 0.98[0.26,3.64]
   
Total (95% CI) 690 632 100% 0.97[0.82,1.15]
Total events: 192 (Lamotrigine), 184 (Placebo)  
Heterogeneity: Tau2=0; Chi2=21.8, df=11(P=0.03); I2=49.54%  
Test for overall effect: Z=0.34(P=0.74)  
Favours Placebo 100.1 50.2 20.5 1 Favours Lamotrigine
 
 
Analysis 1.3.   Comparison 1 E:icacy of add-on lamotrigine
versus placebo - 50% responders, Outcome 3 Best-case scenario.
Study or subgroup Lamotrigine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Baulac 2010 74/141 30/141 29.5% 2.47[1.73,3.52]
Binnie 1989 1/16 1/18 0.93% 1.13[0.08,16.55]
Boas 1996 14/30 4/26 4.21% 3.03[1.14,8.08]
Duchowny 1999 55/98 16/101 15.5% 3.54[2.19,5.74]
Jawad 1989 7/12 1/12 0.98% 7[1.01,48.54]
Loiseau 1990 3/11 1/14 0.87% 3.82[0.46,31.84]
Matsuo 1993 52/143 10/73 13.02% 2.65[1.43,4.91]
Messenheimer 1994 12/46 4/52 3.69% 3.39[1.18,9.79]
Naritoku 2007 73/121 29/122 28.4% 2.54[1.79,3.6]
Schapel 1993 5/20 1/21 0.96% 5.25[0.67,41.1]
Schmidt 1993 2/11 1/12 0.94% 2.18[0.23,20.84]
Smith 1993 10/41 1/40 1% 9.76[1.31,72.74]
   
Total (95% CI) 690 632 100% 2.88[2.36,3.5]
Favours Placebo 100.1 50.2 20.5 1 Favours Lamotrigine
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Study or subgroup Lamotrigine Placebo Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Total events: 308 (Lamotrigine), 99 (Placebo)  
Heterogeneity: Tau2=0; Chi2=5.26, df=11(P=0.92); I2=0%  
Test for overall effect: Z=10.56(P<0.0001)  
Favours Placebo 100.1 50.2 20.5 1 Favours Lamotrigine
 
 
Comparison 2.   Treatment withdrawal (global outcome)





Statistical method Effect size
1 Withdrawal from treatment 14 1806 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.91, 1.37]
1.1 Parallel studies - adults 4 1187 Risk Ratio (M-H, Fixed, 95% CI) 1.17 [0.90, 1.50]
1.2 Parallel studies in children 1 199 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.42, 1.52]
1.3 Cross-over studies 8 382 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [0.89, 3.72]
1.4 Parallel studies in Infants 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.45, 1.06]
 
 
Analysis 2.1.   Comparison 2 Treatment withdrawal (global outcome), Outcome 1 Withdrawal from treatment.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.1.1 Parallel studies - adults  
Baulac 2010 40/141 35/141 26.25% 1.14[0.77,1.69]
Matsuo 1993 19/143 6/73 5.96% 1.62[0.67,3.87]
Naritoku 2007 24/121 16/122 11.95% 1.51[0.85,2.7]
Schachter 1995 53/334 20/112 22.46% 0.89[0.56,1.42]
Subtotal (95% CI) 739 448 66.61% 1.17[0.9,1.5]
Total events: 136 (Treatment), 77 (Control)  
Heterogeneity: Tau2=0; Chi2=2.61, df=3(P=0.45); I2=0%  
Test for overall effect: Z=1.18(P=0.24)  
   
2.1.2 Parallel studies in children  
Duchowny 1999 14/98 18/101 13.29% 0.8[0.42,1.52]
Subtotal (95% CI) 98 101 13.29% 0.8[0.42,1.52]
Total events: 14 (Treatment), 18 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.68(P=0.5)  
   
2.1.3 Cross-over studies  
Binnie 1989 0/16 0/18   Not estimable
Boas 1996 8/30 2/26 1.61% 3.47[0.81,14.89]
Jawad 1989 1/12 0/12 0.37% 3[0.13,67.06]
Loiseau 1990 1/11 1/14 0.66% 1.27[0.09,18.14]
More in controls 2000.005 100.1 1 More in Lamotrigine
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Messenheimer 1994 2/46 4/52 2.82% 0.57[0.11,2.94]
Schapel 1993 0/20 0/21   Not estimable
Schmidt 1993 1/11 0/12 0.36% 3.25[0.15,72.36]
Smith 1993 6/41 3/40 2.28% 1.95[0.52,7.27]
Subtotal (95% CI) 187 195 8.09% 1.82[0.89,3.72]
Total events: 19 (Treatment), 10 (Control)  
Heterogeneity: Tau2=0; Chi2=2.99, df=5(P=0.7); I2=0%  
Test for overall effect: Z=1.65(P=0.1)  
   
2.1.4 Parallel studies in Infants  
Piña-Garza 2008 11/19 16/19 12% 0.69[0.45,1.06]
Subtotal (95% CI) 19 19 12% 0.69[0.45,1.06]
Total events: 11 (Treatment), 16 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.71(P=0.09)  
   
Total (95% CI) 1043 763 100% 1.11[0.91,1.37]
Total events: 180 (Treatment), 121 (Control)  
Heterogeneity: Tau2=0; Chi2=13.05, df=11(P=0.29); I2=15.71%  
Test for overall effect: Z=1.02(P=0.31)  
Test for subgroup differences: Chi2=7.33, df=1 (P=0.06), I2=59.1%  
More in controls 2000.005 100.1 1 More in Lamotrigine
 
 
Comparison 3.   Adverse e:ects





Statistical method Effect size
1 Ataxia 12 1525 Risk Ratio (M-H, Fixed, 99% CI) 3.34 [2.01, 5.55]
1.1 Parallel studies - adults 3 944 Risk Ratio (M-H, Fixed, 99% CI) 3.40 [1.67, 6.90]
1.2 Parallel studies - children 1 199 Risk Ratio (M-H, Fixed, 99% CI) 5.15 [0.72, 36.64]
1.3 Cross-over studies 8 382 Risk Ratio (M-H, Fixed, 99% CI) 2.98 [1.38, 6.41]
2 Dizziness 13 1768 Risk Ratio (M-H, Fixed, 99% CI) 2.00 [1.52, 2.64]
2.1 Parallel studies - adults 4 1187 Risk Ratio (M-H, Fixed, 99% CI) 2.09 [1.49, 2.94]
2.2 Parallel studies - children 1 199 Risk Ratio (M-H, Fixed, 99% CI) 4.33 [1.27, 14.79]
2.3 Cross-over studies 8 382 Risk Ratio (M-H, Fixed, 99% CI) 1.41 [0.83, 2.38]
3 Fatigue 12 1552 Risk Ratio (M-H, Fixed, 99% CI) 0.82 [0.55, 1.22]
3.1 Parallel studies - adults 3 971 Risk Ratio (M-H, Fixed, 99% CI) 0.81 [0.46, 1.42]
3.2 Parallel studies - children 1 199 Risk Ratio (M-H, Fixed, 99% CI) 1.89 [0.54, 6.63]
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Statistical method Effect size
3.3 Cross-over studies 8 382 Risk Ratio (M-H, Fixed, 99% CI) 0.65 [0.34, 1.23]
4 Nausea 12 1486 Risk Ratio (M-H, Fixed, 99% CI) 1.81 [1.22, 2.68]
4.1 Parallel studies - adults 3 905 Risk Ratio (M-H, Fixed, 99% CI) 1.68 [1.02, 2.78]
4.2 Parallel studies - children 1 199 Risk Ratio (M-H, Fixed, 99% CI) 5.67 [0.81, 39.69]
4.3 Cross-over studies 8 382 Risk Ratio (M-H, Fixed, 99% CI) 1.67 [0.85, 3.29]
5 Somnolence 13 1768 Risk Ratio (M-H, Fixed, 99% CI) 1.39 [0.96, 2.00]
5.1 Parallel studies - adults 4 1187 Risk Ratio (M-H, Fixed, 99% CI) 1.58 [0.93, 2.68]
5.2 Parallel studies - children 1 199 Risk Ratio (M-H, Fixed, 99% CI) 1.37 [0.67, 2.81]
5.3 Cross-over studies 8 382 Risk Ratio (M-H, Fixed, 99% CI) 1.06 [0.51, 2.17]
6 Diplopia 3 944 Risk Ratio (M-H, Fixed, 99% CI) 3.79 [2.15, 6.68]
7 Headache 5 1386 Risk Ratio (M-H, Fixed, 99% CI) 1.13 [0.88, 1.45]
 
 
Analysis 3.1.   Comparison 3 Adverse e:ects, Outcome 1 Ataxia.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
3.1.1 Parallel studies - adults  
Baulac 2010 7/141 1/141 2.95% 7[0.45,108.03]
Matsuo 1993 27/143 7/73 27.32% 1.97[0.7,5.5]
Schachter 1995 80/334 6/112 26.48% 4.47[1.56,12.82]
Subtotal (99% CI) 618 326 56.75% 3.4[1.67,6.9]
Total events: 114 (Treatment), 14 (Control)  
Heterogeneity: Tau2=0; Chi2=2.78, df=2(P=0.25); I2=28.14%  
Test for overall effect: Z=4.45(P<0.0001)  
   
3.1.2 Parallel studies - children  
Duchowny 1999 10/98 2/101 5.81% 5.15[0.72,36.64]
Subtotal (99% CI) 98 101 5.81% 5.15[0.72,36.64]
Total events: 10 (Treatment), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.15(P=0.03)  
   
3.1.3 Cross-over studies  
Binnie 1989 1/16 1/18 2.77% 1.13[0.03,38.53]
Boas 1996 1/30 0/26 1.58% 2.61[0.04,165.96]
Jawad 1989 2/12 0/12 1.47% 5[0.11,237.43]
Loiseau 1990 0/11 0/14   Not estimable
Messenheimer 1994 16/46 5/52 13.83% 3.62[1.08,12.16]
More in controls 2000.005 100.1 1 More in Lamotrigine
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Schapel 1993 2/20 1/21 2.88% 2.1[0.1,44.36]
Schmidt 1993 0/11 0/12   Not estimable
Smith 1993 14/41 5/40 14.92% 2.73[0.81,9.2]
Subtotal (99% CI) 187 195 37.45% 2.98[1.38,6.41]
Total events: 36 (Treatment), 12 (Control)  
Heterogeneity: Tau2=0; Chi2=0.92, df=5(P=0.97); I2=0%  
Test for overall effect: Z=3.66(P=0)  
   
Total (99% CI) 903 622 100% 3.34[2.01,5.55]
Total events: 160 (Treatment), 28 (Control)  
Heterogeneity: Tau2=0; Chi2=4.16, df=9(P=0.9); I2=0%  
Test for overall effect: Z=6.12(P<0.0001)  
Test for subgroup differences: Chi2=0.47, df=1 (P=0.79), I2=0%  
More in controls 2000.005 100.1 1 More in Lamotrigine
 
 
Analysis 3.2.   Comparison 3 Adverse e:ects, Outcome 2 Dizziness.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
3.2.1 Parallel studies - adults  
Baulac 2010 12/141 13/141 11.68% 0.92[0.34,2.47]
Matsuo 1993 61/143 20/73 23.79% 1.56[0.9,2.7]
Naritoku 2007 21/121 6/122 5.37% 3.53[1.12,11.1]
Schachter 1995 166/334 20/112 26.91% 2.78[1.62,4.78]
Subtotal (99% CI) 739 448 67.74% 2.09[1.49,2.94]
Total events: 260 (Treatment), 59 (Control)  
Heterogeneity: Tau2=0; Chi2=9.72, df=3(P=0.02); I2=69.13%  
Test for overall effect: Z=5.58(P<0.0001)  
   
3.2.2 Parallel studies - children  
Duchowny 1999 21/98 5/101 4.42% 4.33[1.27,14.79]
Subtotal (99% CI) 98 101 4.42% 4.33[1.27,14.79]
Total events: 21 (Treatment), 5 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=3.07(P=0)  
   
3.2.3 Cross-over studies  
Binnie 1989 2/16 3/18 2.54% 0.75[0.08,6.62]
Boas 1996 11/30 5/26 4.81% 1.91[0.57,6.37]
Jawad 1989 0/12 0/12   Not estimable
Loiseau 1990 0/11 0/14   Not estimable
Messenheimer 1994 12/46 10/52 8.43% 1.36[0.51,3.59]
Schapel 1993 1/20 0/21 0.44% 3.14[0.05,195.86]
Schmidt 1993 5/11 4/12 3.44% 1.36[0.35,5.27]
Smith 1993 12/41 9/40 8.18% 1.3[0.49,3.47]
Subtotal (99% CI) 187 195 27.84% 1.41[0.83,2.38]
Total events: 43 (Treatment), 31 (Control)  
Heterogeneity: Tau2=0; Chi2=1.28, df=5(P=0.94); I2=0%  
Test for overall effect: Z=1.68(P=0.09)  
More in controls 2000.005 100.1 1 More in Lamotrigine
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Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
   
Total (99% CI) 1024 744 100% 2[1.52,2.64]
Total events: 324 (Treatment), 95 (Control)  
Heterogeneity: Tau2=0; Chi2=16.49, df=10(P=0.09); I2=39.37%  
Test for overall effect: Z=6.43(P<0.0001)  
Test for subgroup differences: Chi2=5.61, df=1 (P=0.06), I2=64.33%  
More in controls 2000.005 100.1 1 More in Lamotrigine
 
 
Analysis 3.3.   Comparison 3 Adverse e:ects, Outcome 3 Fatigue.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
3.3.1 Parallel studies - adults  
Baulac 2010 14/141 24/141 29.48% 0.58[0.26,1.31]
Naritoku 2007 6/121 3/122 3.67% 2.02[0.34,12.09]
Schachter 1995 28/334 10/112 18.4% 0.94[0.38,2.32]
Subtotal (99% CI) 596 375 51.55% 0.81[0.46,1.42]
Total events: 48 (Treatment), 37 (Control)  
Heterogeneity: Tau2=0; Chi2=2.99, df=2(P=0.22); I2=33.06%  
Test for overall effect: Z=0.95(P=0.34)  
   
3.3.2 Parallel studies - children  
Duchowny 1999 11/98 6/101 7.26% 1.89[0.54,6.63]
Subtotal (99% CI) 98 101 7.26% 1.89[0.54,6.63]
Total events: 11 (Treatment), 6 (Control)  
Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%  
Test for overall effect: Z=1.31(P=0.19)  
   
3.3.3 Cross-over studies  
Binnie 1989 4/16 3/18 3.47% 1.5[0.26,8.69]
Boas 1996 4/30 7/26 9.21% 0.5[0.12,2.13]
Jawad 1989 3/12 6/12 7.37% 0.5[0.11,2.21]
Loiseau 1990 1/11 0/14 0.55% 3.75[0.06,223.2]
Messenheimer 1994 1/46 2/52 2.31% 0.57[0.03,12.69]
Schapel 1993 3/20 5/21 5.99% 0.63[0.12,3.45]
Schmidt 1993 2/11 2/12 2.35% 1.09[0.11,11.33]
Smith 1993 3/41 8/40 9.95% 0.37[0.07,1.9]
Subtotal (99% CI) 187 195 41.19% 0.65[0.34,1.23]
Total events: 21 (Treatment), 33 (Control)  
Heterogeneity: Tau2=0; Chi2=4.31, df=7(P=0.74); I2=0%  
Test for overall effect: Z=1.74(P=0.08)  
   
Total (99% CI) 881 671 100% 0.82[0.55,1.22]
Total events: 80 (Treatment), 76 (Control)  
Heterogeneity: Tau2=0; Chi2=11.11, df=11(P=0.43); I2=0.99%  
Test for overall effect: Z=1.26(P=0.21)  
Test for subgroup differences: Chi2=3.81, df=1 (P=0.15), I2=47.49%  
More in controls 100.1 50.2 20.5 1 More in Lamotrigine
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Analysis 3.4.   Comparison 3 Adverse e:ects, Outcome 4 Nausea.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
3.4.1 Parallel studies - adults  
Matsuo 1993 31/143 8/73 17.42% 1.98[0.76,5.12]
Naritoku 2007 8/121 3/122 4.91% 2.69[0.49,14.9]
Schachter 1995 73/334 17/112 41.88% 1.44[0.76,2.71]
Subtotal (99% CI) 598 307 64.22% 1.68[1.02,2.78]
Total events: 112 (Treatment), 28 (Control)  
Heterogeneity: Tau2=0; Chi2=1.09, df=2(P=0.58); I2=0%  
Test for overall effect: Z=2.66(P=0.01)  
   
3.4.2 Parallel studies - children  
Duchowny 1999 11/98 2/101 3.24% 5.67[0.81,39.69]
Subtotal (99% CI) 98 101 3.24% 5.67[0.81,39.69]
Total events: 11 (Treatment), 2 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=2.3(P=0.02)  
   
3.4.3 Cross-over studies  
Binnie 1989 1/16 3/18 4.64% 0.38[0.02,6.42]
Boas 1996 3/30 1/26 1.76% 2.6[0.14,46.93]
Jawad 1989 2/12 0/12 0.82% 5[0.11,237.43]
Loiseau 1990 0/11 0/14   Not estimable
Messenheimer 1994 10/46 9/52 13.9% 1.26[0.43,3.63]
Schapel 1993 4/20 1/21 1.6% 4.2[0.26,66.7]
Schmidt 1993 2/11 2/12 3.15% 1.09[0.11,11.33]
Smith 1993 10/41 4/40 6.66% 2.44[0.59,10.01]
Subtotal (99% CI) 187 195 32.54% 1.67[0.85,3.29]
Total events: 32 (Treatment), 20 (Control)  
Heterogeneity: Tau2=0; Chi2=4.44, df=6(P=0.62); I2=0%  
Test for overall effect: Z=1.94(P=0.05)  
   
Total (99% CI) 883 603 100% 1.81[1.22,2.68]
Total events: 155 (Treatment), 50 (Control)  
Heterogeneity: Tau2=0; Chi2=8.16, df=10(P=0.61); I2=0%  
Test for overall effect: Z=3.88(P=0)  
Test for subgroup differences: Chi2=2.49, df=1 (P=0.29), I2=19.73%  
More in controls 200.05 50.2 1 More in Lamotrigine
 
 
Analysis 3.5.   Comparison 3 Adverse e:ects, Outcome 5 Somnolence.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
3.5.1 Parallel studies - adults  
Baulac 2010 15/141 15/141 19.16% 1[0.41,2.43]
Matsuo 1993 22/143 5/73 8.45% 2.25[0.66,7.62]
Naritoku 2007 8/121 5/122 6.36% 1.61[0.39,6.75]
Schachter 1995 46/334 8/112 15.3% 1.93[0.75,4.96]
Subtotal (99% CI) 739 448 49.27% 1.58[0.93,2.68]
More in controls 20.5 1.50.7 1 More in Lamotrigine
Lamotrigine add-on therapy for drug-resistant focal epilepsy (Review)









Cochrane Database of Systematic Reviews
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Total events: 91 (Treatment), 33 (Control)  
Heterogeneity: Tau2=0; Chi2=2.6, df=3(P=0.46); I2=0%  
Test for overall effect: Z=2.24(P=0.03)  
   
3.5.2 Parallel studies - children  
Duchowny 1999 24/98 18/101 22.64% 1.37[0.67,2.81]
Subtotal (99% CI) 98 101 22.64% 1.37[0.67,2.81]
Total events: 24 (Treatment), 18 (Control)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.14(P=0.25)  
   
3.5.3 Cross-over studies  
Binnie 1989 2/16 4/18 4.81% 0.56[0.07,4.36]
Boas 1996 0/30 1/26 2.05% 0.29[0,18.44]
Jawad 1989 3/12 0/12 0.64% 7[0.16,300.92]
Loiseau 1990 1/11 0/14 0.57% 3.75[0.06,223.2]
Messenheimer 1994 9/46 4/52 4.8% 2.54[0.59,10.92]
Schapel 1993 1/20 6/21 7.48% 0.18[0.01,2.51]
Schmidt 1993 0/11 0/12   Not estimable
Smith 1993 5/41 6/40 7.76% 0.81[0.19,3.47]
Subtotal (99% CI) 187 195 28.09% 1.06[0.51,2.17]
Total events: 21 (Treatment), 21 (Control)  
Heterogeneity: Tau2=0; Chi2=9.24, df=6(P=0.16); I2=35.04%  
Test for overall effect: Z=0.2(P=0.84)  
   
Total (99% CI) 1024 744 100% 1.39[0.96,2]
Total events: 136 (Treatment), 72 (Control)  
Heterogeneity: Tau2=0; Chi2=12.72, df=11(P=0.31); I2=13.53%  
Test for overall effect: Z=2.3(P=0.02)  
Test for subgroup differences: Chi2=1.35, df=1 (P=0.51), I2=0%  
More in controls 20.5 1.50.7 1 More in Lamotrigine
 
 
Analysis 3.6.   Comparison 3 Adverse e:ects, Outcome 6 Diplopia.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Baulac 2010 16/141 2/141 7.16% 8[1.19,53.88]
Matsuo 1993 52/143 6/73 28.46% 4.42[1.55,12.6]
Schachter 1995 109/334 12/112 64.38% 3.05[1.47,6.33]
   
Total (99% CI) 618 326 100% 3.79[2.15,6.68]
Total events: 177 (Treatment), 20 (Control)  
Heterogeneity: Tau2=0; Chi2=1.76, df=2(P=0.42); I2=0%  
Test for overall effect: Z=6.06(P<0.0001)  
More in controls 100.1 50.2 20.5 1 More in Lamotrigine
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Analysis 3.7.   Comparison 3 Adverse e:ects, Outcome 7 Headache.
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 99% CI   M-H, Fixed, 99% CI
Baulac 2010 32/141 28/141 19.21% 1.14[0.63,2.07]
Duchowny 1999 18/98 15/101 10.14% 1.24[0.54,2.82]
Matsuo 1993 46/143 19/73 17.26% 1.24[0.68,2.24]
Naritoku 2007 20/121 18/122 12.3% 1.12[0.52,2.42]
Schachter 1995 125/334 40/112 41.1% 1.05[0.72,1.52]
   
Total (99% CI) 837 549 100% 1.13[0.88,1.45]
Total events: 241 (Treatment), 120 (Control)  
Heterogeneity: Tau2=0; Chi2=0.5, df=4(P=0.97); I2=0%  
Test for overall effect: Z=1.22(P=0.22)  
More in controls 100.1 50.2 20.5 1 More in Lamotrigine
 
 







Stroop time Smith 1993 41 93.98 98.39
Stroop error Smith 1993 44 2.18 2.41
Stroop colour word (Total score) Banks 1991 10 32.4+/-10.9 35.6+/-9.42
Number cancellation: AC Smith 1993 44 51.36 49.7
Number cancellation: AE Smith 1993 43 3.6 3.04
Number cancellation: BC Smith 1993 42 48.21 48.54
Number cancellation: C Smith 1993 42 38.19 39.29
Critical flicker fusion Smith 1993 40 30.44 30.37
Choice reaction time Smith 1993 40 0.675 0.669
Digit symbol (Scaled score) Banks 1991 10 5 +/-2.45 6.6 +/- 2.71
Rey complex figure recall percentile Banks 1991 10 22+/-17.51 30.5+/-27.33
Trail making part B percentile Banks 1991 10 26+/-30.35 30.5+/-32.09











Table 2.   Health-related quality of life outcomes (Smith 1993) 
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PSYCHOLOGICAL        
Depression 54 4.24 4.26 No significant difference
Happiness 51 3.8 1.96 Higher scores in LTG group; P = 0.003
Mood 50 24.36 26.8 No significant difference
Self-esteem 50 30.06 29.16 No significant difference
Mastery 50 20.02 18.78 Higher scores in LTG group; P = 0.003
Anxiety 54 6.87 6.83 No significant difference
PHYSICAL (Nottingham
Health Profile)
       
Energy 53 0.68 0.68 No significant difference
Pain 53 0.6 0.69 No significant difference
Emotional reaction 53 1.96 1.96 No significant difference
Sleep 53 0.89 0.76 No significant difference
Social isolation 53 0.92 0.94 No significant difference
Physical mobility 53 0.96 0.91 No significant difference
SEIZURE SEVERITY SCALE        
Percept 53 25.19 25.47 No significant difference
Ictal 53 19.47 20.53 Less severe seizures in LTG group; P = 0.017
Caregivers 53 20.35 21.80 Less severe seizures in LTG group; P = 0.035




A P P E N D I C E S
Appendix 1. Cochrane Register of Studies (CRS Web)
1. MESH DESCRIPTOR Lamotrigine EXPLODE ALL AND CENTRAL:TARGET
2. (elmendos OR epilepax OR lamictal OR lamictin OR lamotrigin*):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET
3. #1 OR #2
4. MESH DESCRIPTOR Epilepsies, Partial EXPLODE ALL AND CENTRAL:TARGET
5. ((partial or focal) and (seizure* or epilep*)):AB,KW,KY,MC,MH,TI AND CENTRAL:TARGET
6. #4 OR #5 AND CENTRAL:TARGET
7. #3 AND #6
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8. (monotherap* NOT (adjunct* OR "add-on" OR "add on" OR adjuvant* OR combination* OR polytherap*)):TI AND CENTRAL:TARGET
9. #7 NOT #8
10. #9 AND >13/12/2018:CRSCREATED
Appendix 2. MEDLINE (Ovid) 1946-
This strategy includes the Cochrane Highly Sensitive Search Strategy for identifying randomized trials (Lefebvre 2019).
1. exp Lamotrigine/
2. (elmendos or epilepax or lamictal or lamictin or lamotrigin$).tw.
3. 1 or 2
4. exp Epilepsies, Partial/
5. ((partial or focal) and (seizure$ or epilep$)).tw.
6. 4 or 5
7. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
8. clinical trials as topic.sh.
9. trial.ti.
10. 7 or 8 or 9
11. exp animals/ not humans.sh.
12. 10 not 11
13. 3 and 6 and 12
14. (monotherap$ not (adjunct$ or "add-on" or "add on" or adjuvant$ or combination$ or polytherap$)).ti.
15. 13 not 14
16. limit 15 to ed=20181206-20200309
17. 15 not (1$ or 2$).ed.
18. 17 and (2018$ or 2019$ or 2020$).dt.
19. 16 or 18
20. remove duplicates from 19
W H A T ' S   N E W
 
Date Event Description
9 March 2020 New search has been performed Searches updated 09 March 2020; no new studies were identi-
fied.
9 March 2020 New citation required but conclusions
have not changed
Conclusions remain unchanged.
The term 'partial' has been replaced by 'focal', in accordance
with the most recent classification of epilepsies of the Interna-
tional League Against Epilepsy (Scheffer 2017).
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H I S T O R Y
Protocol first published: Issue 1, 2000
Review first published: Issue 3, 2000
 
Date Event Description
28 May 2015 New citation required but conclusions
have not changed
Conclusions remain unchanged.
28 May 2015 New search has been performed Searches updated 28 May 2015. No new relevant studies were
identified.
6 January 2010 New search has been performed Searches updated 6th January 2010. Two new studies have been
included (Naritoku 2007 and Piña-Garza 2008); the conclusions
are unchanged.
10 September 2008 Amended Converted to new review format.
25 April 2007 New search has been performed Searches updated 25th April 2007. One new conference abstract
(Carignani 2006) has been added to the 'Studies Awaiting Clas-
sification' section. This will be assessed for inclusion at a later
date.
16 November 2005 Amended We re-ran our search on 31 March 2005. One new study (Carig-
nani 2004) has been added to the 'studies awaiting assessment'
section. 
 
C O N T R I B U T I O N S   O F   A U T H O R S
Mariangela Panebianco was primarily responsible for the writing of this update and completed data extraction and 'Risk of bias'
assessments. The same author assessed the studies for eligibility, extracted data, and assessed risk of bias. The assessment and
interpretation of psychological data was done by Gus Baker in the original version of this review. Anthony Marson and Rebecca Bresnahan
provided guidance and manuscript feedback during the update process. Rebecca Bresnahan was responsible for GRADE-assessing
evidence.




AGM: A consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management in Hospitals
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Internal sources
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External sources
• National Institute for Health Research (NIHR), UK.
This review update was funded by the National Institute for Health Research (NIHR) [Clinically e@ective treatments for central nervous
system disorders in the NHS, with a focus on Epilepsy and Movement Disorders (SRPG project 16/114/26)]. The views expressed are
those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Changes have been made to the format and content of the methods from the original protocol, in line with current MECIR standards (MECIR
2012) and the Cochrane Style Manual.
We have replaced the term 'partial' with 'focal', and 'refractory' with 'drug-resistant' in accordance with the most recent classification of
epilepsies of the International League Against Epilepsy (Sche@er 2017).
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